365 related articles for article (PubMed ID: 15857930)
1. Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes.
Raju R; Dalakas MC
Brain; 2005 Aug; 128(Pt 8):1887-96. PubMed ID: 15857930
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of TGF-beta1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin.
Amemiya K; Semino-Mora C; Granger RP; Dalakas MC
Clin Immunol; 2000 Feb; 94(2):99-104. PubMed ID: 10637094
[TBL] [Abstract][Full Text] [Related]
3. Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies.
Barbasso Helmers S; Dastmalchi M; Alexanderson H; Nennesmo I; Esbjörnsson M; Lindvall B; Lundberg IE
Ann Rheum Dis; 2007 Oct; 66(10):1276-83. PubMed ID: 17277004
[TBL] [Abstract][Full Text] [Related]
4. High-dose intravenous immunoglobulin in inflammatory myopathies: experience based on controlled clinical trials.
Dalakas MC
Neurol Sci; 2003 Oct; 24 Suppl 4():S256-9. PubMed ID: 14598055
[TBL] [Abstract][Full Text] [Related]
5. Upregulated inducible co-stimulator (ICOS) and ICOS-ligand in inclusion body myositis muscle: significance for CD8+ T cell cytotoxicity.
Schmidt J; Rakocevic G; Raju R; Dalakas MC
Brain; 2004 May; 127(Pt 5):1182-90. PubMed ID: 15047591
[TBL] [Abstract][Full Text] [Related]
6. Effects of interleukin-1beta, interleukin-13 and transforming growth factor-beta on gene expression in human airway smooth muscle using gene microarrays.
Jarai G; Sukkar M; Garrett S; Duroudier N; Westwick J; Adcock I; Chung KF
Eur J Pharmacol; 2004 Aug; 497(3):255-65. PubMed ID: 15336943
[TBL] [Abstract][Full Text] [Related]
7. Intravenous immunoglobulin in patients with anti-GAD antibody-associated neurological diseases and patients with inflammatory myopathies: effects on clinicopathological features and immunoregulatory genes.
Dalakas MC
Clin Rev Allergy Immunol; 2005 Dec; 29(3):255-69. PubMed ID: 16391401
[TBL] [Abstract][Full Text] [Related]
8. Signal transducer and activator of transcription 1 in human muscle: implications in inflammatory myopathies.
Illa I; Gallardo E; Gimeno R; Serrano C; Ferrer I; Juárez C
Am J Pathol; 1997 Jul; 151(1):81-8. PubMed ID: 9212734
[TBL] [Abstract][Full Text] [Related]
9. Platelet-endothelial cell adhesion molecule-1 and CD146: soluble levels and in situ expression of cellular adhesion molecules implicated in the cohesion of endothelial cells in idiopathic inflammatory myopathies.
Figarella-Branger D; Schleinitz N; Boutière-Albanèse B; Camoin L; Bardin N; Guis S; Pouget J; Cognet C; Pellissier JF; Dignat-George F
J Rheumatol; 2006 Aug; 33(8):1623-30. PubMed ID: 16881117
[TBL] [Abstract][Full Text] [Related]
10. Alpha-chemokine receptors CXCR1-3 and their ligands in idiopathic inflammatory myopathies.
De Paepe B; De Keyzer K; Martin JJ; De Bleecker JL
Acta Neuropathol; 2005 Jun; 109(6):576-82. PubMed ID: 15937690
[TBL] [Abstract][Full Text] [Related]
11. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies.
Dastmalchi M; Grundtman C; Alexanderson H; Mavragani CP; Einarsdottir H; Helmers SB; Elvin K; Crow MK; Nennesmo I; Lundberg IE
Ann Rheum Dis; 2008 Dec; 67(12):1670-7. PubMed ID: 18272672
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic approaches in patients with inflammatory myopathies.
Dalakas MC
Semin Neurol; 2003 Jun; 23(2):199-206. PubMed ID: 12894385
[TBL] [Abstract][Full Text] [Related]
13. Provision of an explanation for the inefficacy of immunotherapy in sporadic inclusion body myositis: quantitative assessment of inflammation and β-amyloid in the muscle.
Zschüntzsch J; Voss J; Creus K; Sehmisch S; Raju R; Dalakas MC; Schmidt J
Arthritis Rheum; 2012 Dec; 64(12):4094-103. PubMed ID: 22941914
[TBL] [Abstract][Full Text] [Related]
14. Immunopathogenic pathways in canine inflammatory myopathies resemble human myositis.
Shelton GD; Hoffman EP; Ghimbovschi S; Peters IR; Day MJ; Mullins M; Moore PF; Nagaraju K
Vet Immunol Immunopathol; 2006 Sep; 113(1-2):200-14. PubMed ID: 16797723
[TBL] [Abstract][Full Text] [Related]
15. The role of high-dose immune globulin intravenous in the treatment of dermatomyositis.
Dalakas MC
Int Immunopharmacol; 2006 Apr; 6(4):550-6. PubMed ID: 16504918
[TBL] [Abstract][Full Text] [Related]
16. Decreased expression of interleukin-1alpha, interleukin-1beta, and cell adhesion molecules in muscle tissue following corticosteroid treatment in patients with polymyositis and dermatomyositis.
Lundberg I; Kratz AK; Alexanderson H; Patarroyo M
Arthritis Rheum; 2000 Feb; 43(2):336-48. PubMed ID: 10693873
[TBL] [Abstract][Full Text] [Related]
17. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments.
Basta M; Dalakas MC
J Clin Invest; 1994 Nov; 94(5):1729-35. PubMed ID: 7962520
[TBL] [Abstract][Full Text] [Related]
18. Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients.
Cherin P; Piette JC; Wechsler B; Bletry O; Ziza JM; Laraki R; Godeau P; Herson S
J Rheumatol; 1994 Jun; 21(6):1092-7. PubMed ID: 7932419
[TBL] [Abstract][Full Text] [Related]
19. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis.
Greenberg SA; Pinkus JL; Pinkus GS; Burleson T; Sanoudou D; Tawil R; Barohn RJ; Saperstein DS; Briemberg HR; Ericsson M; Park P; Amato AA
Ann Neurol; 2005 May; 57(5):664-78. PubMed ID: 15852401
[TBL] [Abstract][Full Text] [Related]
20. The cell-specific expression of metalloproteinase-disintegrins (ADAMs) in inflammatory myopathies.
Dehmel T; Janke A; Hartung HP; Goebel HH; Wiendl H; Kieseier BC
Neurobiol Dis; 2007 Mar; 25(3):665-74. PubMed ID: 17207628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
